Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Treatment-related risk factors for premature menopause following Hodgkin lymphoma

Marie L. De Bruin, Jeannine Huisbrink, Michael Hauptmann, Marianne A. Kuenen, Gabey M. Ouwens, Mars B. van't Veer, Berthe M. P. Aleman, Flora E. van Leeuwen

Blood (2008) 111 (1): 101–108.

https://doi.org/10.1182/blood-2007-05-090225

Published: 2008

Journal Articles

First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma.

Mars B. Van’t Veer, MD, PhD, Annelise Notenboom, PhD, Marius McKenzie, MD,PhD, Hanneke Kluin-Nelemans, MD,PhD, Rien van Oers, MD,PhD, Jose Zijlstra, MD, Daphne de Jong, MD,PhD, Pieter Sonneveld, MD,PhD, Anton Hagenbeek, MD,PhD

Blood (2006) 108 (11): 2734.

https://doi.org/10.1182/blood.V108.11.2734.2734

Published: 2006

Journal Articles

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Frank Morschhausser, Martin Wolf, John Seymour, Herve Tilly, Michael Pfreundschuh, Hanneke Kluin-Nelemans, John Raemaekers, Mars B. van’t Veer, Noel Milpied, Guillaume Cartron, Antonio Pezzutto, Andrew Spencer, Christelle Darstein, Donald Thornton, Martin Dreyling, Felix Reyes

Blood (2006) 108 (11): 2450.

https://doi.org/10.1182/blood.V108.11.2450.2450

Published: 2006

Journal Articles

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Houchingue Eghbali, MD, Pauline Brice, MD, Geert-Yan Creemers, MD, Marinus van Marwijk Kooij, MD, Patrice Carde, MD, Mars B. Van’t Veer, MD, Elli Lugtenburg, MD, Anne Sonet, MD, Catherine Sebban, MD, Michel Blanc, MD, John M. Raemaekers, MD, Laurent Voillat, MD, Chantal Rieux, Ed M. Noordijk, MD, Michel Henry-Amar, MD

Blood (2005) 106 (11): 814.

https://doi.org/10.1182/blood.V106.11.814.814

Published: 2005

Journal Articles

Predictive Value of Gene Expression with Respect to IgVH Mutational Status and Survival in Chronic Lymphocytic Leukemia.

Mars B. Van’t Veer, PhD, Anne Brooymans, Anton W. Langerak, PhD, Wilfried J. Graveland, Kirsten Van Lom, PhD, Peter Valk, PhD

Blood (2004) 104 (11): 1913.

https://doi.org/10.1182/blood.V104.11.1913.1913

Published: 2004

NARROW

Treatment-related risk factors for premature menopause following Hodgkin lymphoma

First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Predictive Value of Gene Expression with Respect to IgVH Mutational Status and Survival in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Treatment-related risk factors for premature menopause following Hodgkin lymphoma

First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Predictive Value of Gene Expression with Respect to IgVH Mutational Status and Survival in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only